France AI Precision Medicine Market Insight
Published: 28 September 2026 | Report Format: Electronic (PDF) | Author: Govind and Krishna
The France AI precision medicine market is forecast to show notable growth at a CAGR of 22.81% because of the growing use of AI in genomics, the need for personalized treatment strategies, increased digitalization efforts in the healthcare industry, and investments in data-based decision-making tools
France AI Precision Medicine Market Insights Forecasts to 2035
- The France AI Precision Medicine Market Size Was Estimated USD 2.8 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 22.81% from 2025 to 2035
- The France AI Precision Medicine Market Size is Expected to rise around USD 21.85 Million by 2035
Notable Insights for the France AI Precision Medicine Market
- The component-based segmentation depicts the dominance of the Software segment in the France AI Precision Medicine Market in 2024 because of rising use of AI algorithms for genomic testing, disease diagnosis, and treatment plans.
- The application-based market segmentation reveals the dominance of Diagnostics & Screening as a market adopter as a result of increased use of AI clinical decision support and precision diagnostics solutions within healthcare organizations.
- Total global income for Illumina, Inc. for the fiscal year 2025 is over $4.2 billion, due to the high demands for genomic sequencing tools and precision medicine products employed in AI-enabled healthcare settings.
- As anticipated, higher adoption of machine learning, predictive analytics, and AI genomics systems, alongside the growing collaboration between hospitals and biotech companies, will contribute to market growth where AI precision medicine technology enables more effective personalization and decision-making.
Download the eBook (ToC)
Research Methodologies Used to Analyze the France AI Precision Medicine Market
The France AI precision medicine market is analyzed by a blend of primary and secondary research approaches for ensuring accurate information about the market and its forecasted performance. Primary research is conducted through discussions with healthcare technology providers, biotechnology companies, pharmaceutical firms, research institutes, healthcare organizations, and experts to analyze demand trends, technological progress, and competitive activities. Secondary research will involve analyzing reports published by companies and governments, industry journals, scientific papers, healthcare databases, genomics publications, and industry organizations in connection with artificial intelligence and precision medicine sectors. Market estimation, trend analysis, and forecasting methods will be used for estimating market size, growth opportunities, price dynamics, and investments.
Decisions Advisors Research Methodology: Trusted Insights for Strategic Decision-Making
What is Decisions Advisors Research?
Decisions Advisors research delivers comprehensive market intelligence through detailed industry analysis, competitive benchmarking, trend forecasting, and data-driven business insights. Our research methodology combines advanced analytical frameworks with extensive primary and secondary research to help organizations make informed and strategic business decisions.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the France AI Precision Medicine Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in France AI Precision Medicine Market
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- QIAGEN N.V.
- Agilent Technologies, Inc.
- Danaher Corporation
- Siemens Healthineers AG
- Oracle Corporation
- GE HealthCare Technologies Inc.
- Koninklijke Philips N.V.
- IBM Corporation
Recent Developments:
- In June 2026, Illumina has introduced the StrataMap Spatial Solution, a complete spatial whole transcriptome research solution for offering genomic information with high resolution for disease research, biomarker discovery, and applications of precision medicine.
- In May 2026, QIAGEN has also partnered with NVIDIA with the objective of integrating graph-based artificial intelligence technology and bioinformatics expertise into QIAGEN’s Digital Insights portfolio. The platform helps in speeding up the identification of disease pathways, drug targets, and biomarkers.
Market Segmentation:
France AI Precision Medicine Market, By Component
- Software
- Hardware
- Services
France AI Precision Medicine Market, By Technology
- Machine Learning
- Deep Learning
- Natural Language Processing (NLP)
- Predictive Analytics
- Genomic Data Analytics
France AI Precision Medicine Market, By Application
- Diagnostics & Screening
- Drug Discovery & Development
- Therapeutics
- Clinical Decision Support
- Disease Risk Prediction
Expert Views:
The development of the AI precision medicine markets in France will be driven by the increased usage of artificial intelligence in the health sector, increased investments in genomics studies, and the growing demand for individualized treatment methods. The application of machine learning techniques, predictive analytics tools, AI-enabled diagnostic solutions, and genomic intelligence tools will result in better health outcomes and increased demand from hospitals, research institutes, pharmaceutical companies, biotech firms, and precision healthcare facilities in France.
Author: Govind and Krishna By Decisions Advisors and Consulting